Rate of Death Up in Year After Non-Fatal Opioid Overdose

Share this content:
Rate of Death Up in Year After Non-Fatal Opioid Overdose
Rate of Death Up in Year After Non-Fatal Opioid Overdose

THURSDAY, June 21, 2018 (HealthDay News) -- There is a marked excess of deaths among U.S. adults who experience a non-fatal opioid overdose, according to a study published online June 20 in JAMA Psychiatry.

Mark Olfson, M.D., M.P.H., from Columbia University in New York City, and colleagues examined a cohort of patients aged 18 to 64 years who were Medicaid beneficiaries and experienced non-fatal opioid overdoses. Data were included from 2001 through 2007; the primary cohort included 76,325 adults with 66,736 person-years of follow-up.

The researchers found that there were 5,194 deaths during the first year after non-fatal opioid overdose, with a crude death rate of 778.3 per 10,000 person-years and an all-cause standardized mortality rate ratio (SMR) of 24.2. Substance use-associated diseases, diseases of the circulatory system, and cancer were the most common immediate causes of death (26.2, 13.2, and 10.3 percent, respectively). SMRs were significantly elevated for every cause examined, especially with respect to drug use-associated diseases (SMR, 132.1), HIV (SMR, 45.9), chronic respiratory diseases (SMR, 41.1), viral hepatitis (SMR, 30.6), and suicide (SMR, 25.9), particularly suicide among females (SMR, 47.9).

"Adults who survive an opioid overdose are at high risk of dying in the year after the incident, not only from drug use-associated causes but also from suicide and a wide range of general medical diseases," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »